Sintilimab in combination with anlotinib in non-small cell lung cancer patients with uncommon EGFR mutations: A phase II, single-arm, prospective study

被引：0
|
作者：
Chen, K. [1 ]
Fan, Y. [1 ]
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Thorac Oncol, Canc Hosp, Hangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
21P
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [21] Current management of uncommon EGFR mutations in non-small cell lung cancer
    Trinh, Jonathan Q.
    Abughanimeh, Omar
    CURRENT PROBLEMS IN CANCER, 2024, 49
  • [22] Neoadjuvant toripalimab plus chemotherapy in patients with potentially resectable non-small cell lung cancer: A prospective, single-arm, phase II trial (Renaissance Study)
    Yan, S.
    Chen, J.
    Wang, J.
    Lv, C.
    Bi, J.
    Yang, X.
    Li, S.
    Wang, Y.
    Li, X.
    Yang, Y.
    Wu, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S1400 - S1400
  • [23] Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)
    Bo Zhang
    Chunlei Shi
    Zhiqiang Gao
    Hua Zhong
    Liwen Xiong
    Aiqin Gu
    Weimin Wang
    Tianqing Chu
    Wei Zhang
    Huimin Wang
    Xueyan Zhang
    Runbo Zhong
    Baohui Han
    BMC Cancer, 22
  • [24] Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)
    Zhang, Bo
    Shi, Chunlei
    Gao, Zhiqiang
    Zhong, Hua
    Xiong, Liwen
    Gu, Aiqin
    Wang, Weimin
    Chu, Tianqing
    Zhang, Wei
    Wang, Huimin
    Zhang, Xueyan
    Zhong, Runbo
    Han, Baohui
    BMC CANCER, 2022, 22 (01)
  • [25] Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study
    Ji, Y.
    Wang, X.
    Lou, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S979 - S979
  • [26] Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: A single-arm, multicenter, phase II trial
    Chen, H.
    Hu, Y.
    Fan, Y.
    Wu, G.
    Cang, S.
    Yang, Y.
    Yang, N.
    Ma, R.
    Jing, G.
    Liu, A.
    Xu, X.
    Tang, S.
    Cheng, Y.
    Yu, Y.
    Wu, Y-L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S53 - S53
  • [27] A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
    Zhou, L.
    Zhang, X.
    Zhang, W.
    Liu, L.
    Xiubao, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S1392 - S1392
  • [28] A multicenter single-arm phase II study of nab-paclitaxel/carboplatin for non-small cell lung cancer patients with interstitial lung disease
    Usui, Y.
    Kenmotsu, H.
    Mori, K.
    Ono, A.
    Yoh, K.
    Baba, T.
    Fujiwara, Y.
    Yamaguchi, O.
    Ko, R.
    Okamoto, H.
    Yamamoto, N.
    Ninomiya, T.
    Ogura, T.
    Kato, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [29] Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial
    Lu, Zhi-qin
    Cai, Jing
    Wang, Xia
    Wei, Jian-ping
    Zeng, Zhi-min
    Huang, Long
    Liu, An-wen
    THORACIC CANCER, 2021, 12 (02) : 172 - 180
  • [30] Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study
    Jung, H. A.
    Park, S.
    Lee, S. -H.
    Ahn, J. S.
    Ahn, M. -J.
    Sun, J. -M.
    ESMO OPEN, 2023, 8 (06)
12345